CRISPR Therapeutics AG
CRSP
Classement en actions
#3541
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering... CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
Prix de l'action
$50.26
Dernière synchronisation: 2026-10-20
Capitalisation boursière
$4.86B
Changement (1 jour)
0.43%
Changement (1 an)
-30.51%
Pays
CH
Échange CRISPR Therapeutics AG (CRSP)
Catégorie
Healthcare
Ratio P/E pour CRISPR Therapeutics AG (CRSP)
Ratio P/E au October 2026 TTM : -10.55
Selon les derniers rapports financiers et le cours de l'action de CRISPR Therapeutics AG, le ratio P/E actuel (TTM) est de -10.55. À la fin de l’année 2023, le P/E de l’entreprise était de -32.28.
Historique du ratio P/E pour CRISPR Therapeutics AG de 2014 à 2026
Ratio P/E à la fin de chaque année
| Année | Ratio P/E | Changez |
|---|---|---|
| 2026 (TTM) | -10.55 | 16.32% |
| 2024 | -9.07 | -71.92% |
| 2023 | -32.28 | 564.18% |
| 2022 | -4.86 | -131.90% |
| 2021 | 15.24 | -152.65% |
| 2020 | -28.94 | -158.41% |
| 2019 | 49.55 | -696.60% |
| 2018 | -8.31 | -39.51% |
| 2017 | -13.73 | 28.29% |
| 2016 | -10.70 | -33.03% |
| 2015 | -15.98 | -73.67% |
| 2014 | -60.71 | 0.00% |
Ratio P/E pour des entreprises similaires ou concurrentes
| Entreprise | P/E Ratio | Différence du P/E Ratio | Pays |
|---|---|---|---|
| 28.78 | -372.80% |
US
|
|
| -28.36 | 168.79% |
US
|
|
| -24.57 | 132.85% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -387.48% |
NL
|
Comment lire un P/E ratio ?
Le ratio Prix/Bénéfice (P/E Ratio) mesure la relation entre le cours de l'action d'une entreprise et ses bénéfices par action.
Un P/E bas mais positif indique une entreprise qui génère des bénéfices élevés par rapport à sa valorisation et qui pourrait être sous-évaluée. Un P/E négatif élevé (proche de 0) indique des pertes importantes.
Les entreprises avec un P/E supérieur à 30 ou négatif sont généralement considérées comme des "actions de croissance", ce qui signifie que les investisseurs s'attendent à ce qu'elles se développent ou deviennent rentables.
Les entreprises avec un P/E positif inférieur à 10 sont généralement considérées comme des "actions de valeur", car elles sont déjà très rentables mais avec peu de potentiel de croissance.